Good news | Basecare has won the honorary titles of "Unicorn" and "Gazelle" in the National Independent Innovation Demonstration Zone of Southern Jiangsu Province
On November 10, the Southern Jiangsu National Independent Innovation Demonstration Zone released the evaluation results of “Unicorn” and “Gazelle” enterprises in 2020, and Suzhou Basecare Medical Devices Co., Ltd. (hereinafter referred to as “Basecare”) once again be awarded the honorary title of "Unicorn" and "Gazelle" in the creation area of southern Jiangsu, which indicates that Basecare continues to be highly recognized and fully affirmed by the relevant departments of the Jiangsu Provincial Government in terms of development potential, innovation capabilities, industry status, and development scale.
Unicorn enterprises and gazelle enterprises are the weather vane to measure the level of regional innovation and development, and they are also an important starting point for the construction of the province's high-tech zones and self-developed areas in southern Jiangsu. As a national high-tech enterprise in Suzhou Industrial Park, Basecare is committed to the research and development and clinical application of high-throughput sequencing technology in the field of reproductive health. It has established a full life cycle product chain and built a complete one-stop service system around the field of eugenic genetics. At present, it has a production center of 1364 square meters and a research center of 6281 square meters.
Let couples with fertility needs no longer encounter fertility difficulties! As a leading enterprise in the field of reproductive health, Basecare is committed to promoting the popularity of the PGT-A technology. The preimplantation genetic testing for aneuploidy kit (PGT-A kit) produced by Basecare is the first PGT-A product in China that has obtained the “special approval for innovative medical devices”. The test kit also obtained the industry’s first medical device registration certificate (Approval No.: 20203400181), filling the technical gap in the clinical application of preimplantation genetic testing technology in China, marking the beginning of a new era, in which China’s preimplantation genetic testing technology is licensed and under official supervision.Frost Sullivan's research data shows that the size of China's assisted reproduction market is about 100 billion yuan, the market for preimplantation genetic testing has increased from about 300 million yuan in 2015 to 2.5 billion yuan in 2019, with a compound growth rate of 70.8%, and is expected to reach 25 billion yuan in 2024.The innovative technology of preimplantation genetic testing provides new options for infertile couples, and brings new hope for expectant couples carrying genetic diseases.